Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 1739-1750, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Doorn, J.
Right arrow Articles by van Buul-Offers, S. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Doorn, J.
Right arrow Articles by van Buul-Offers, S. C.
Related Collections
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2002;48:1739-1750.)
© 2002 American Association for Clinical Chemistry, Inc.

Antibodies Directed against the E Region of Pro-Insulin-like Growth Factor-II Used to Evaluate Non-Islet Cell Tumor-induced Hypoglycemia

Jaap van Doorn1a, Cok M. Hoogerbrugge1, Johanna G. Koster1, Ruud J. Bloemen1, Klaas Hoekman2, Aart H. Mudde3 and Sylvia C. van Buul-Offers1

1 Department of Pediatrics, Laboratory of Endocrinology, Wilhelmina Children’s Hospital/University Medical Center Utrecht, 3508 AB Utrecht, The Netherlands.

2 Department of Medical Oncology, Free University Medical Center, 1007 MB Amsterdam, The Netherlands.

3 Slingeland Hospital, 7000 AD Doetinchem, The Netherlands.

aAddress correspondence to this author at: Laboratory of Endocrinology, Department of Pediatrics, Room KE 03-139.2, Wilhelmina Children’s Hospital/University Medical Center Utrecht, PO Box 85090, 3508 AB Utrecht, The Netherlands. Fax 31-30-2505378; e-mail J.vandoorn{at}lab.azu.nl.

Background: Detection of incompletely processed precursor forms of insulin-like growth factor-II ("big" IGF-II) in plasma is essential for both the diagnosis and follow-up of non-islet cell tumor-induced hypoglycemia (NICTH) and may be relevant to other diseases as well. RIA using an antibody raised against a synthetic peptide consisting of the first 21 amino acids of the E domain [E(68–88)] of human pro-IGF-II cannot distinguish between E-peptide-containing big IGF-II and cleaved E domain or fragments. We therefore developed and validated an ELISA that specifically detects big IGF-II in plasma.

Methods: The ELISA used a solid-phase antibody to E(68–88) and a liquid-phase monoclonal hIGF-II antibody. Pro-IGF-II purified from normal human plasma was used as a calibrator. Acid Sep-Pak C18 extracts of plasma from NICTH patients were analyzed, and the results were compared with those obtained for plasma samples from healthy individuals. In addition, blood specimens derived from dialyzed patients with chronic renal failure, which contained relatively high concentrations of cleaved E domain or fragments, were studied. The results were validated by acid Sephadex G-50 gel filtration.

Results: Results from this ELISA indicated that the concentration of big IGF-II in NICTH plasma was higher (mean ± SD, 22.6 ± 9.4 nmol/L) than in normal plasma (3.8 nmol/L). Conversely, the concentrations in pooled CRF plasma (2.0 ± 0.8 nmol/L) were low. Antibodies directed against either E(68–88) or E(13–134) of pro-IGF-II could be used to detect these peptides in tumor tissue by immunohistochemistry.

Conclusions: The possibility of quantifying pro-IGF-II by ELISA in plasma represents a potentially useful tool for the diagnosis and follow-up of NICTH and should facilitate further in vitro and in vivo studies on its regulation and function in humans.




The following articles in journals at HighWire Press have cited this article:


Home page
 Endocr Relat CancerHome page
J. W. B de Groot, B. Rikhof, J. van Doorn, H. J G Bilo, M. A Alleman, A. H Honkoop, and W. T A van der Graaf
Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases
Endocr. Relat. Cancer, December 1, 2007; 14(4): 979 - 993.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
Q. Qiu, J.-Y. Jiang, M. Bell, B. K. Tsang, and A. Gruslin
Activation of Endoproteolytic Processing of Insulin-Like Growth Factor-II in Fetal, Early Postnatal, and Pregnant Rats and Persistence of Circulating Levels in Postnatal Life
Endocrinology, October 1, 2007; 148(10): 4803 - 4811.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
U. Espelund, J. M. Bruun, B. Richelsen, A. Flyvbjerg, and J. Frystyk
Pro- and mature IGF-II during diet-induced weight loss in obese subjects
Eur. J. Endocrinol., December 1, 2005; 153(6): 861 - 869.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.